ConductScience.org, home

Paper · 36934116

Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity.

Patra T and 5 others. NPJ Vaccines, 2023. Cited by 35 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity. Papers, record 36934116. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36934116

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity.
PubMed
Journal
NPJ Vaccines
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
35
iCite
Relative citation ratio, by iCite
3.82
iCite
Revised in PubMed
2026-04-08
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Patra TTapashttps://orcid.org/0000-0002-3388-1719
2Meyer KKeith
3Haga YYuki
4Reagan EKErin Khttps://orcid.org/0000-0003-3162-4636
5Weissman DDrew
6Ray RRanjit

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 AI124429NIAID NIH HHSUnited StatesR01AI124429PubMedNIH RePORTER
R01 DK058023NIDDK NIH HHSUnited StatesR01DK058023PubMed and NIHNIH RePORTER
R01 DK122401NIDDK NIH HHSUnited StatesR01DK122401PubMedNIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116,103,160Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.J Virol2005https://conductscience.org/library/papers/16103160PubMed
222,171,278Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization.J Virol2012https://conductscience.org/library/papers/22171278PubMed
335,612,312Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response.J Virol2022https://conductscience.org/library/papers/35612312PubMed
420,677,942Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.J Infect Dis2010https://conductscience.org/library/papers/20677942PubMed
522,084,442Granzyme B regulates antiviral CD8+ T cell responses.J Immunol2011https://conductscience.org/library/papers/22084442PubMed
629,443,378Hepatitis C Virus E2 Envelope Glycoprotein Induces an Immunoregulatory Phenotype in Macrophages.Hepatology2019https://conductscience.org/library/papers/29443378PubMed
717,977,972Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus.J Virol2008https://conductscience.org/library/papers/17977972PubMed
824,583,033The past, present and future of neutralizing antibodies for hepatitis C virus.Antiviral Res2014https://conductscience.org/library/papers/24583033PubMed
925,275,133Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.J Virol2014https://conductscience.org/library/papers/25275133PubMed
1032,016,547Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.Arch Virol2020https://conductscience.org/library/papers/32016547PubMed

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.

PMIDTitleJournalYearIn PapersSource
42,827,179Immunopharmacological design of a multi-epitope vaccine targeting hepatitis C virus genotype 3a.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/42827179PubMed
42,514,657Overcoming Antigenic Drift in PEDV: Broadly Protective Antigen Design and sIgA-Driven Lactogenic Immunity.Vet Sci2026https://conductscience.org/library/papers/42514657PubMed
42,368,401Trivalent mRNA-LNP Vaccine Induces Robust Humoral and Cellular Immunity in Mice: Preclinical Evaluation for Porcine Enteric Coronaviruses.Int J Nanomedicine2026https://conductscience.org/library/papers/42368401PubMed
42,347,630Therapeutic Vaccines for Chronic Viral Infections: From Immune Modulation to Clinical Translation.Vaccines (Basel)2026https://conductscience.org/library/papers/42347630PubMed
42,129,447Deglycosylation of hepatitis C virus pseudoparticles with 2-3,6,8,9 Neuraminidase A elicits protective neutralizing antibodies in mice.Sci Rep2026https://conductscience.org/library/papers/42129447PubMed
41,939,904Hepatitis C virus E1 protein-specific linear B-cell epitopes, pan-genotype reactivity, and functional relevance.Front Immunol2026https://conductscience.org/library/papers/41939904PubMed
41,772,850Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH).Liver Int2026https://conductscience.org/library/papers/41772850PubMed
41,750,254Targeted Removal of HCV E2 N2 N-Glycan Is Associated with Improved Immune Responses in Mice.Biomolecules2026https://conductscience.org/library/papers/41750254PubMed
41,649,705Nanoparticle approaches for hepatitis therapy and clinical translation.Discov Nano2026https://conductscience.org/library/papers/41649705PubMed
41,185,028A trimer ancestral spike-based mRNA vaccine confers cross-generational protection against SADS-CoV.J Nanobiotechnology2025https://conductscience.org/library/papers/41185028PubMed

1 to 10 of 27

See all 27 cited by

Genes10

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36934116

GET https://conductscience.org/api/papers/v1/36934116/references?page=2